NCT01562015View on ClinicalTrials.gov

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

November 30, 2014

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Ganetespib

Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).

Trial Locations (5)

33612

Synta Pharmaceuticals Investigative Site, Tampa

44195

Synta Pharmaceuticals Investigative Site, Cleveland

ON L8V 5C2

Synta Pharmaceuticals Investigative Site, Hamilton

K1H 8L6

Synta Pharmaceuticals Investigative Site, Ottawa

M5G 2M9

Synta Pharmaceuticals Investigative Site, Toronto

All Listed Sponsors
lead

Synta Pharmaceuticals Corp.

INDUSTRY

NCT01562015 - A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter